KalVista Pharmaceuticals (KALV) Appoints Laurence Reid to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors
November 26, 2024 7:00 AM ESTCAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Companys Board of Directors, effective immediately. Dr. Reid brings more than three decades of experience with a track record of leadership and company-building success.
I am pleased to welcome Dr. Reid, with his deep expertise in high-growth biotech companies, to the KalVista Board of Directors, said Ben Palleiko, Chief Executive Officer of KalVista. His extensive biopharmaceutical and strategic experience will be a tremendous asset as the Company continues to progress... More
